CN1748707A - Use of ivermectin in treating seborrhea and using method - Google Patents
Use of ivermectin in treating seborrhea and using method Download PDFInfo
- Publication number
- CN1748707A CN1748707A CN 200410074798 CN200410074798A CN1748707A CN 1748707 A CN1748707 A CN 1748707A CN 200410074798 CN200410074798 CN 200410074798 CN 200410074798 A CN200410074798 A CN 200410074798A CN 1748707 A CN1748707 A CN 1748707A
- Authority
- CN
- China
- Prior art keywords
- ivermectin
- smear
- cream
- continue
- lotion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The ivermectin preparations for treating seborrhea include liniment and cream. The ivermectin liniment is water solution of ivermectin in the concentration of 750mcg/ml; and the ivermectin cream includes ivermectin in effective treating amount and supplementary material.
Description
Technical field
The present invention has made up the Therapeutic Method of seborrheic dermatitis, form by the mixture of smearing a kind of lotion or cream, under the situation of lotion, this mixture comprises the ivermectin aqueous solution for the treatment of effective dose, this concentration of aqueous solution is about 750 mcg/ml, if as cream, then wrap acceptable accessories, smear a kind of like this lotion or cream every night and continue seven days, on the basis of keeping, used one to four time in every month then.
Technical background
Known seborrheic eczema and the seborrhea of also claiming of seborrheic dermatitis, it is a kind of chronic superficial inflammation disease of skin, a lot of positions of health be can influence, scalp, eyebrow, muffle, pleat trace, lip, ear, breast, sternal region, axillary fossa, mammary gland underfold, umbilicus, groin and line of gluteal fold trace comprised.This disease is a feature with a lot of shapes, size and superficial makings, often be the crust sample, yellowish and with pruritus.
The etiology of seborrheic dermatitis, pathogeny and histology are pendent, but it is in clinical very similar psoriasis, a lot of research worker believe that these two kinds of diseases share a kind of relevant etiology, can wide disease that can be narrow although psoriasis is a kind of range of definition, what wherein psoriasis was different from seborrheic dermatitis usually is that it does not exist pruritus, compounds for treating there is drug resistance, for example selenium sulfide and pyrrole sulfur zinc, they have been used for the seborrhea treatment of diseases.
In addition some people owing to zinc deficiency, and other people think that its etiology is aspect microorganism the fat dermatitis.Other has the influence that other people believe hormone, because this disease can not appear at before the adolescence, also there is hypothesis to think, there is a kind of special fungus to cause various forms of seborrheic dermatitiss, like this, being regarded as convictive a kind of argument is yeast, is this at least a reason wherein that dermatitis is taken place, and it is the common form of this class fungus.
The reflection seborrheic dermatitis is that the prior art of this viewpoint of zinc deficiency is the United States Patent (USP) NO.5 of Akiko etc., 997,852 (1999), denomination of invention is the dermatitis medicine, and think seborrhea dermatitis and because microorganism and advocate that thus theory with antibiotic therapy is reflected in the US Patent No of Rosenberg etc.: 4,965, in 936 (1986), denomination of invention is for using imidazoles antibiotic topical therapeutic psoriasis, like this, Rosenberg etc. are considered as pathogenicity psoriasis and pathogenicity seborrheic dermatitis to be equal to, because this situation, also often adopt polymycin B-hydrocortisone, promptly a kind of antibiotic of cortisone that contains is as local medicinal liquid.
The present invention identifies oneself seborrheic dermatitis in essence by fungus-caused theory, like this, caused by molecular weight biology maximum in the microcosmic biological spectrum, just greater than antibacterial but still be the sightless biology of human eye, they comprise still undetected microorganism, sensitivity is treated in local her rhzomorph smelting responded.
Summary of the invention
The present invention has made up the Therapeutic Method of seborrheic dermatitis, form by the mixture of smearing a kind of lotion or cream, under the situation of lotion, this mixture comprises the ivermectin aqueous solution for the treatment of effective dose, this concentration of aqueous solution is about 750 mcg/ml, if as cream, then comprise acceptable accessories, smear a kind of like this lotion or cream every night and continue seven days, on the basis of keeping, used one to four time in every month then
Therefore, an object of the present invention is to provide the local treatment of effective treatment seborrheic dermatitis
Another purpose provides the method for this class dermatitis of safe and effective treatment, and this method from then on will be for the permanent effect that alleviates basically.
Following detailed description of the invention and the claims of enclosing will make above-mentioned and other purposes of the present invention and advantage become apparent
Detailed description of the invention
Ivermectin is a part that is known as in the big class chemicals of 13-deoxysaccharide aglucon, the present invention has become Merck and Co. in history about its topical use, Ine., Rahway, a kind of product of New Jersey, it is used for the veterinary in history and uses, be used for the treatment of animal body endoparasitism rerum natura disease, but, some medical article, particularly come from the third world and hot geographic medical article and pointed out the topical use of ivermectin in people inside or endoparasite disease therapeutic, for example fly larvae and onchocerciasis, but, these diseases and seborrheic dermatitis or thus and do not exist known pathogenicity or histology to get in touch between the psoriasis of any form known, and then, just known to the inventor, there is not document once to point out the topical application of ivermectin in any type of dermatitis of treatment.
The present invention relates to treat the purposes of effective dose ivermectin, generally obtain its paste from Merck, when water-soluble, other is to form the lotion that concentration is at least 750 mcg/ml, perhaps, can form the cream of ivermectin, it is combined with the adjuvant accepted pharmaceutically, for example with propylene glycol, sodium lauryl sulfate, xanthan gum or its combination
Smear lotion or cream continue seven days every day on diseased region then, each month one to four time after this, more then every month once, with prophylactic recurrence.
About the mechanism of action, ivermectin relates generally to sebaceous gland to the effect of skin, the latter is present in almost each folliculus of application on human skin, being subject to fungus attacks, therefore, be suitable for the fungus theory and the hormone malfunction theory of seborrheic dermatitis in this, and, owing to prove that the ivermectin medication has relaxation effect to skin, also be suitable for and emotional stress and the relevant relevant etiology theory of perspiration increase, these reactions are the reasons that cause seborrheic dermatitis, like this, the antiinflammatory of ivermectin and desensitization it is reported it is the changeableness that suppresses motor, thereby reduce the capillary tube stress relevant with disease.
The inventor is at Ormond Beach, Florida lasts about 7 years experiment to about 100 patients, the result who finds said method is not only safely but also significantly effectively in the treatment of various object for appreciation solidity seborrheic dermatitiss, and then, after the patient being used ivermectin according to suitable scheme, do not see the recurrence of disease, and, not relevant with prior art Drug therapy, particularly local antibiotic side effect occurs, for example allergia stimulation or burn.Thereby when I use above-mentioned ivermectin lotion and cream, also do not run into the patient and produce any autoimmune response, and this is a situation of utilizing antibiotic therapy to fall in, for example erythromycin, tetracycline and imidazoles, therefore, I believe and have had been found that effectively and the method for the treatment seborrheic dermatitis of general safety almost, and this method can have other value having jointly in the etiology type curing psoriasis with seborrheic dermatitis.
The specific embodiment:
1. although shown and described the preferred embodiment of the present invention, the self-evident the present invention of being can be presented as the concrete demonstration of this paper and describe mode in addition, and in said embodiment, can carry out certain this change with arranging in the form of partial content, and not deviating from basis of the present invention design or principle, the latter is illustrated in the claims of enclosing.
2. in the Therapeutic Method of seborrheic dermatitis, comprise the following step
(a) use the ivermectin of effective dose and the lotion that water forms
(b) smear described lotion to diseased region every day and continue about seven days;
(c) repeat to smear one to four time in every month and continue some months
3. claims 1 described method, the treatment effective dose of wherein said Yi Wei bacterium comprises the concentration of at least 750 mcg/ml.
4. as method as described in the claim 2, wherein this method further comprises the following step:
(d) smear about each moon of described lotion afterwards once in described step (c)
5. the Therapeutic Method of seborrheic dermatitis comprises the following step:
(a) use treatment effective dose ivermectin and acceptable accessories to form cream:
(b) smear described cream to diseased region every day and continue about seven days:
(c) repeat to smear one to four time in every month and continue some months
6. as method as described in the claim 4, the treatment effective dose of wherein said ivermectin comprises the concentration of at least 750 mcg/ml in described cream
7. as method as described in the claim 5, wherein said acceptable accessories is selected from the preparation of being made up of propylene glycol, sodium lauryl sulfate, xanthan gum and combination thereof
8. as method as described in the claim 4, further comprise the following step:
(d) smear about every month of described cream afterwards once in described step (c).
Claims (7)
1. in the Therapeutic Method of seborrheic dermatitis, comprise the following step
A) use the ivermectin of effective dose and the lotion that water forms
B) smear described lotion to diseased region every day and continue about seven days;
C) repeat to smear one to four time in every month and continue some months
2. claims 1 described method, the treatment effective dose of wherein said Yi Wei bacterium comprises the concentration of at least 750 mcg/ml.
3. as method as described in the claim 2, wherein this method further comprises the following step:
(d) smear about each moon of described lotion afterwards once in described step (c)
4. the Therapeutic Method of seborrheic dermatitis comprises the following step:
A) use treatment effective dose ivermectin and acceptable accessories to form cream:
B) smear described cream to diseased region every day and continue about seven days:
C) repeat to smear one to four time in every month and continue some months
5. as method as described in the claim 4, the treatment effective dose of wherein said ivermectin comprises the concentration of at least 750 mcg/ml in described cream
6. as method as described in the claim 5, wherein said acceptable accessories is selected from the preparation of being made up of propylene glycol, sodium lauryl sulfate, xanthan gum and combination thereof
7. as method as described in the claim 4, further comprise the following step:
(d) smear about every month of described cream afterwards once in described step (c).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410074798 CN1748707A (en) | 2004-09-16 | 2004-09-16 | Use of ivermectin in treating seborrhea and using method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410074798 CN1748707A (en) | 2004-09-16 | 2004-09-16 | Use of ivermectin in treating seborrhea and using method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1748707A true CN1748707A (en) | 2006-03-22 |
Family
ID=36604484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410074798 Pending CN1748707A (en) | 2004-09-16 | 2004-09-16 | Use of ivermectin in treating seborrhea and using method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1748707A (en) |
-
2004
- 2004-09-16 CN CN 200410074798 patent/CN1748707A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1171588C (en) | Method of treatment of seborrheic dermatitis | |
CA2866527C (en) | Use of isoeugenol esters in treating hyperpigmentation | |
EP1450785B1 (en) | Method of treating dermatoses using avermectin compound | |
CN1319020A (en) | Extracts of feverfew (tanacetum parthenium) against inflammatory disorders | |
US20030185915A1 (en) | Synergetic composition for the treatment of psoriasis and other skin disorders and method therefor | |
EP0988040B1 (en) | Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain | |
CN104127422B (en) | A kind of composition and method of making the same for the treatment of pruritus and comedo | |
Sharifi-Heris et al. | A review study of diaper rash dermatitis treatments | |
US7897559B2 (en) | Dermatological composition and kit containing avermectin compound for treating dermatological conditions | |
Rapaport | Granuloma annulare caused by injectable collagen | |
CN1748707A (en) | Use of ivermectin in treating seborrhea and using method | |
Kim et al. | Dermatology for the allergist | |
CN1247227C (en) | External-use liposome prepn for treating mite-borne dermatosis | |
CN114452292B (en) | Application of pulsatilla saponin B4 in preparation of skin care products | |
Liao et al. | Seborrheic Dermatitis | |
KR20240104289A (en) | Composition for alleviating pain and method for alleviating pain using the same | |
EP4277592A1 (en) | Topical composition | |
Surana et al. | Updated Review on: Cucurbita Maxima (Pumpkin Seed) oil for acne relief patches | |
ES2645535T3 (en) | Topical compositions to treat inflammatory disorders, diseases and ailments | |
CN117838686A (en) | Application of sparganolide B in preparing medicament for preventing or treating acne | |
CN115969765A (en) | Composition with skin sensitivity relieving function and cosmetic thereof | |
Serum et al. | The Causes of Skin Inflammation and How to Treat It | |
CN107296809A (en) | A kind of externally-applied medicinal composition for treating psoriasis | |
WO2015044763A1 (en) | Valerolactam derivatives for dermal/transdermal delivery of molecules | |
CN106668006A (en) | Application of composition of 3-methyl-1-phenyl-2-pyrazoline-5-ketone and (+)2-borneol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Yao Chunxia Document name: Notice of publication of application for patent for invention |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Yao Chunxia Document name: Notification before expiration of term |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Yao Chunxia Document name: Notification that Application Deemed to be Withdrawn |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |